{
  "report_rows": [
    {
      "kpi": "Q2 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.216B vs. cons ~$1.202B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.28 vs. cons ~$3.21",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "CAG Diagnostics recurring organic revenue growth",
      "prediction": "IN-LINE",
      "answer": "pred ~10.2% vs. cons ~9.8%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 revenue guidance",
      "prediction": "BETTER",
      "answer": "guide ~$4.70B-$4.79B vs. cons ~$4.75B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$14.60-$15.05 vs. cons ~$14.88 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 CAG Diagnostics recurring organic growth guidance",
      "prediction": "BETTER",
      "answer": "guide ~9.0%-11.0% vs. cons ~9.8% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 U.S. same-store clinical-visit assumption",
      "prediction": "UNCHANGED",
      "answer": "guide ~-1.5% vs. cons ~-1.5% (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 6.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$0.07 EPS beat versus ~$3.21 consensus alongside a FY2026 EPS midpoint of ~$14.83 versus ~$14.88 consensus initially supports upward revisions if recurring growth holds near ~10.2% versus ~9.8% consensus; the modest guide raise and durable volume/innovation mix should outweigh the instrument-revenue lap.",
  "day5_confidence": "MEDIUM"
}